Clinical Trials Logo

Citation(s)

  •   Hollander P, Cooper J, Bregnhøj J, Pedersen CB
    A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients w

Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Details for clinical trial NCT00097084